RxDoctor Payments Data

Chelsea Shugars, MD

Neurology · Chattanooga, TNNPI 1003261231

Payments from drug & device makers

$46,959in general payments, 2019–2025

Across 368 payments — averaging $127.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$18K
  • Tanabe Pharma America, Inc.$8K
  • Natus Medical Incorporated$7K
  • Amylyx Pharmaceuticals, Inc.$4K
  • Argenx US, Inc.$3K
  • AstraZeneca$3K
  • plus $5K from 40 others

What the payments were for

  • Consulting fees$20,75144%
  • Speaking & faculty fees$16,33735%
  • Travel & lodging$1,4853%
  • Food & beverage$8,38718%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,959 in reported general payments places this provider in the 80th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$80,149
Medicare patients
171
Services billed
4,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone73$1,016,905
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc14$775,018
HizentraImmun Glob G(Igg)/Pro/Iga 0-5026$412,556
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5036$291,549
Gamunex-CImmune Globul G/Gly/Iga Avg 4637$201,034
RelyvrioSod Phenylbutyrat/Taurursodiol11$133,336
Riluzole62$7,514
Mycophenolate Mofetil40$7,321
Pyridostigmine Bromide57$4,153
Gabapentin137$3,540
Pyridostigmine Bromide ErPyridostigmine Bromide13$1,456
Azathioprine16$492
Baclofen46$479
Duloxetine Hcl31$406
Pregabalin27$389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart Hytrulo$3,151$775,01814 claims
CSL BehringHizentra$417$412,55626 claims
Grifols USA, LLCGamunex-C$23$201,03437 claims
Amylyx Pharmaceuticals, Inc.Relyvrio$3,723$133,33611 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$18$11,47597 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 neurology providers in Tennessee.

Other neurology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →